OrbiMed Advisors PALI Position
Active4-Fund ConvergenceOrbiMed Advisors initiated a new position in PALISADE BIO, INC. (PALI) in Q4 2025, holding $4.4M worth of shares across 1,871,420 shares.
PALI is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 16.4% of float with 8.2 days to cover, indicating significant bearish positioning against OrbiMed's long thesis.
About PALISADE BIO, INC.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Full company profile →Short Interest
16.4%
8.2 days to cover
Frequently Asked Questions
Does OrbiMed Advisors own PALI?
Yes. As of Q4 2025, OrbiMed Advisors holds 1,871,420 shares of PALISADE BIO, INC. (PALI) valued at $4.4M. This data comes from their SEC 13F filing.
How many hedge funds own PALI?
4 specialist biotech hedge funds currently hold PALI, including Perceptive Advisors, Commodore Capital, RA Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy PALI?
OrbiMed Advisors's position in PALI was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's PALI position increasing or decreasing?
OrbiMed Advisors initiated a new position in PALI in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PALICompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →